Rhodia to undergo twin accounting probes

- Last updated on GMT

Related tags: Rhodia, Stock, Corporate governance, Finance

Rhodia is facing two separate investigations for alleged accounting
irregularities as well as insider trading, just as the financial
difficulties afflicting the French chemicals group have started to

The first action, undertaken by France's stock market regulator the Autorité des Marchés Financiers, concerns financial disclosures starting from 31 December, 2000, and has emerged just as Rhodia has suggested it may return to profit next year after four years of posting losses.

The AMF alleges that Rhodia breached disclosure relating to its valuation of ChiRex, a pharmaceutical ingredient manufacturer it bought in 2000, in 2003. Two other claimed violations include Rhodia's valuations of deferred tax assets and debt, liquidity and the environment, Rhodia said in a statement.

The action is the result of a financial investigation into Rhodia that stated in 2000, and could result in financial penalties, although the company said it did not expect these to be severe even if they are imposed. The AMF will deliver its verdict in a few months, during which time it will hear testimony from Rhodia.

Separately, France's public prosecutor also said late last week that the company is being investigated for accounting irregularities and insider trading. This action stems from complaints filed in 2003 by Edouard Stern, the banker and former Rhodia board member who was found dead in his Geneva apartment earlier this month.

Stern was among board members seeking to oust former Rhodia chief executive Jean-Pierre Tirouflet in 2003, before Tirouflet was replaced by current CEO Jean-Pierre Clamadieu, who has been the architect of Rhodia's recovery with swingeing job cuts and the disposal of assets.

The alleged accounting improprieties predate Clamadieu's accession to the CEO post.

Related news

Show more

Related products

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us


View more